These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

814 related items for PubMed ID: 33730350

  • 1. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S, Shih JY, Jang TW, Liam CK, Yu Y.
    Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
    [Abstract] [Full Text] [Related]

  • 2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Boland A, Bates V, Vecchio F, Dundar Y, Chaplin M, Green JA.
    Cochrane Database Syst Rev; 2021 Mar 18; 3(3):CD010383. PubMed ID: 33734432
    [Abstract] [Full Text] [Related]

  • 3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.
    Cochrane Database Syst Rev; 2016 May 25; (5):CD010383. PubMed ID: 27223332
    [Abstract] [Full Text] [Related]

  • 4. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ, Drilon A, Santini FC.
    Lung Cancer; 2019 Nov 25; 137():113-122. PubMed ID: 31568888
    [Abstract] [Full Text] [Related]

  • 5. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E, Pavilack M, Espirito JL, Clark J, Fernandes A.
    Adv Ther; 2020 Feb 25; 37(2):946-954. PubMed ID: 31955357
    [Abstract] [Full Text] [Related]

  • 6. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M, Jaipuria J, Mattoo S, Dhandha S, Khatri M.
    Clin Oncol (R Coll Radiol); 2022 Nov 25; 34(11):e451-e462. PubMed ID: 35810049
    [Abstract] [Full Text] [Related]

  • 7. Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
    Chang HC, Huang KT, Tseng CC, Chen YM, Lai CH, Chang YP, Chen YC, Chuang HY, Wang CC.
    Thorac Cancer; 2023 Nov 25; 14(32):3217-3225. PubMed ID: 37704454
    [Abstract] [Full Text] [Related]

  • 8. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
    Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Tsuya A, Fukuoka M, Minami H.
    Jpn J Clin Oncol; 2024 Mar 09; 54(3):319-328. PubMed ID: 37997468
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.
    Hung LJ, Hsu PC, Yang CT, Kuo CS, Chang JW, Huang CY, Chang CF, Wu CE.
    Aging (Albany NY); 2024 Jan 08; 16(1):550-567. PubMed ID: 38194721
    [Abstract] [Full Text] [Related]

  • 10. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
    Kwok WC, Ho JCM, Tam TCC, Ip MSM, Lam DCL.
    Thorac Cancer; 2022 Jul 08; 13(14):2057-2063. PubMed ID: 35668712
    [Abstract] [Full Text] [Related]

  • 11. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
    Chang HC, Wang CC, Tseng CC, Huang KT, Chen YM, Chang YP, Lai CH, Fang WF, Lin MC, Chuang HY.
    Thorac Cancer; 2023 Nov 08; 14(32):3208-3216. PubMed ID: 37737541
    [Abstract] [Full Text] [Related]

  • 12. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M, Singhal MK, Kamle MS.
    Indian J Cancer; 2022 Mar 08; 59(Supplement):S80-S89. PubMed ID: 35343193
    [Abstract] [Full Text] [Related]

  • 13. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Tamiya M, Tamiya A, Suzuki H, Moriizumi K, Nakahama K, Taniguchi Y, Kunimasa K, Kimura M, Inoue T, Kuhara H, Nishino K, Hirashima T, Atagi S, Imamura F, Kumagai T.
    Anticancer Res; 2019 Jul 08; 39(7):3923-3929. PubMed ID: 31262922
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ.
    Int J Cancer; 2019 Jun 01; 144(11):2887-2896. PubMed ID: 30485437
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
    Masood A, Kancha RK, Subramanian J.
    Semin Oncol; 2019 Jun 01; 46(3):271-283. PubMed ID: 31558282
    [Abstract] [Full Text] [Related]

  • 16. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat.
    Ont Health Technol Assess Ser; 2010 Jun 01; 10(24):1-48. PubMed ID: 23074402
    [Abstract] [Full Text] [Related]

  • 17. Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study.
    Manninen O, Puuniemi L, Iivanainen S, Arffman M, Kaarteenaho R, Koivunen JP.
    Acta Oncol; 2023 Dec 01; 62(12):1854-1861. PubMed ID: 37934101
    [Abstract] [Full Text] [Related]

  • 18. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
    Popat S, Jung HA, Lee SY, Hochmair MJ, Lee SH, Escriu C, Lee MK, Migliorino MR, Lee YC, Girard N, Daoud H, Märten A, Miura S.
    Lung Cancer; 2021 Dec 01; 162():9-15. PubMed ID: 34649106
    [Abstract] [Full Text] [Related]

  • 19. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study).
    Pasello G, Vicario G, Zustovich F, Oniga F, Gori S, Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C, Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M, Menis J, Corte DD, Frega S, Guarneri V, Conte P, Veneto Oncology Network.
    Oncologist; 2019 Jun 01; 24(6):e318-e326. PubMed ID: 30846513
    [Abstract] [Full Text] [Related]

  • 20. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep 01; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.